603087 Stock Overview
A biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Gan & Lee Pharmaceuticals. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥48.25 |
| 52 Week High | CN¥62.90 |
| 52 Week Low | CN¥32.10 |
| Beta | 1.62 |
| 11 Month Change | 26.81% |
| 3 Month Change | 6.72% |
| 1 Year Change | 11.00% |
| 33 Year Change | -31.86% |
| 5 Year Change | n/a |
| Change since IPO | -25.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 603087 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 3.3% | 1.7% | 2.7% |
| 1Y | 11.0% | -10.5% | 4.6% |
Return vs Industry: 603087 exceeded the CN Biotechs industry which returned -10.5% over the past year.
Return vs Market: 603087 exceeded the CN Market which returned 4.6% over the past year.
Price Volatility
| 603087 volatility | |
|---|---|
| 603087 Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 7.6% |
| 10% most volatile stocks in CN Market | 11.5% |
| 10% least volatile stocks in CN Market | 5.3% |
Stable Share Price: 603087 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603087's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 4,482 | Kai Du | www.ganlee.com |
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. The company’s products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro and lispro mix 75/25 injection; Prandilin 25, an insulin lispro injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection. It also offers GanleePen, an insulin injection device; GanleeFine, an insulin pen needle; and medical devices.
Gan & Lee Pharmaceuticals. Fundamentals Summary
| 603087 fundamental statistics | |
|---|---|
| Market cap | CN¥28.81b |
| Earnings (TTM) | CN¥504.82m |
| Revenue (TTM) | CN¥2.69b |
57.1x
P/E Ratio10.7x
P/S RatioIs 603087 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603087 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.69b |
| Cost of Revenue | CN¥746.80m |
| Gross Profit | CN¥1.95b |
| Other Expenses | CN¥1.44b |
| Earnings | CN¥504.82m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 23, 2024
| Earnings per share (EPS) | 0.85 |
| Gross Margin | 72.27% |
| Net Profit Margin | 18.74% |
| Debt/Equity Ratio | 0% |
How did 603087 perform over the long term?
See historical performance and comparison